[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","gyky6fowb1wci6pbdgqoj4azw","revision",2,"title","Moleculin Biotech 公布 2026 年 10 月 16 日投资者简报","originalTitle","Moleculin Biotech, Inc. (0001659617) (Filer)","summary","Moleculin Biotech 公布 2026 年 10 月 16 日投资者简报。简报内容包含公司最新财务与业务信息。该简报作为 8-K 文件附件 99.1 公开。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-16T13:29:32.000Z","discoveredAt","2026-10-16T13:35:15.448Z","timelineAt","category","tip","tags",[81,82,83],"stockSymbols",[80],"score",21,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f0RBmvYWHPNw",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","237d4bb4-ea94-47e3-8087-36221bc57939","Moleculin Biotech 公布投资者简报",{"_72":73,"_15":74},"zh","

UNITED STATES\n

SECURITIES AND EXCHANGE COMMISSION\n

WASHINGTON, D.C. 20549\n

FORM 8-K\n

CURRENT REPORT\n

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934\n

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 16, 2026\n

\n $\"logobig.jpg\"$ \n

MOLECULIN BIOTECH, INC.\n

(Exact Name of Registrant as Specified in its Charter)

\n\n \n \n \n \n\n

Delaware

001-37758

47-4671997

(State or Other Jurisdiction of

Incorporation or Organization)

(Commission File No.)

(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007\n

(Address of principal executive offices and zip code)

(713) 300-5160\n

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

\n\n \n \n\n

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n \n \n\n

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n \n \n\n

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n \n \n\n

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐\n

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

\n\n \n \n \n \n\n

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

\n\n \n \n\n

Item 7.01

Regulation FD Disclosure

On October 16, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

\n\n \n \n\n

Item 9.01

Financial Statements and Exhibits.

\n\n \n \n\n

(d)

Exhibits.

\n\n \n \n\n

Exhibit No.

Description

\n\n \n \n\n

99.1	Investor Presentation dated October 16, 2026

\n\n \n \n\n

104	Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE\n

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n

	MOLECULIN BIOTECH, INC.


	Date:	October 16, 2026

	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster

","zhKind","complete","MBRX","政策与监管","退市","IPO","aihot","/items/gyky6fowb1wci6pbdgqoj4azw","https://www.sec.gov/Archives/edgar/data/1659617/000143774926032762/0001437749-26-032762-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792368000&sig=7b6974b5a67903ec","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792368000&sig=85dc13f192a3fa85 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792368000&sig=7b2f7276301ea6d9 96w","changelogVersion","2026-10-01T08:00"]